Hepatocyte growth factor is an endogenous pleiotropic factor shown to act as a potent neuroprotectant against disease progression in animal models of amyotrophic lateral sclerosis, which is a devastating, adult-onset motor neuron disease. To evaluate the safety, tolerability, and pharmacokinetics of recombinant 5-residue-deleted human hepatocyte growth factor (KP-100) injected intrathecally through an implantable catheter connected to a subcutaneous port, we conducted a first-in-human phase I trial of intrathecal KP-100 in 15 Japanese patients with amyotrophic lateral sclerosis. The regimen was a single injection of 3 escalating doses (0.2, 0.6, and 2.0 mg/body) in 9 subjects followed by 2 doses (0.6 and 2.0 mg/body) repeated 5 times at 1-week intervals in 6 subjects (3 subjects/group). With single-dose administration, the mean half-life of KP-100 in the cerebrospinal fluid was 1.2 to 1.4 days, with its maximum concentration increasing in a dose-dependent manner. With multiple-dose administration, the trough KP-100 concentrations in the cerebrospinal fluid generally remained constant for any dose, despite multiple dosing. There were no deaths, serious adverse events, or device malfunctions leading to discontinuation. In all subjects, plasma KP-100 concentrations were <1 ng/mL, or below the lower limit of detection at all time points of measurement. Anti-KP-100 antibody was not detected in the cerebrospinal fluid or plasma specimens from any of the subjects throughout the KP-100 dosing period. These results suggest that KP-100, as well as the device used to administer it, is safe and tolerable. A phase II trial is warranted in patients with various central nervous system diseases such as amyotrophic lateral sclerosis.
ameliorate the environment in which nerves degenerate in order to rebuild the nervous system, including its glial cell component. Accordingly, the development of therapies using neurotrophic factors to promote motor neuron survival, such as neurotrophin, is expected.
In Japan, oral riluzole 9 and intravenous edaravone 10 are approved as ALS therapeutics for inhibiting the disease progression; however, no effective treatment to improve symptoms of ALS has been established. The approach to ALS therapeutics development is based on several hypotheses, such as excessive glutamate toxicity, oxidative stress, insufficient transport of neurotrophic factors from peripheral skeletal muscles, and immune abnormality. Neurotrophic factors, one of the therapeutic candidates, were initially developed by systemic administration. 11 Although insulin-like growth factor 1 significantly increased survival in a North American clinical trial, 12 it did not do so in a European study. 13 Thereafter, to improve their delivery to the diseased central nervous system (CNS), intrathecal infusion was employed for clinical trials; however, therapeutic effects of insulin-like growth factor 1, 14 brain-derived neurotrophic factor 15, 16 and ciliary neurotrophic factor 17 has not been sufficiently demonstrated to date. Nevertheless, intrathecal administration of more potent neurotrophic factors being able to protect motor units are still appreciated 11 because ALS is a multifactorial motor neuron disease.
Identified, purified, and cloned as mature hepatocyte growth factor (HGF), 18 HGF has been shown to promote cell proliferation, migration, and differentiation; to suppress apoptosis; to promote organogenesis and vascularization; and to have other effects not only on hepatocytes but also on many other types of cells. 19 In addition, since Honda et al 20 reported the neurotrophic effect of HGF on nerve cells, more details of the effects of HGF on the nervous system have been uncovered. 21 HGF has been shown to be active in survival promotion, dendrite elongation, and differentiation promotion, and to act alone or in cooperation with other neurotrophic factors in primary cultures of various nerve cells, including motor neurons. 20 Furthermore, HGF has been reported to improve the functions of nerve cells as well as glial cells and to modify gliosis. 22, 23 Five-residue-deleted human HGF (dHGF) is a variant existing naturally in the living human organism, and is nearly equivalent to full-length HGF in terms of bioactivity and physicochemical and pharmacologic characteristics. 24 With dHGF as an active ingredient, KP-100 is currently under development both in and outside Japan. Based on a first-in-human phase I study of intrathecal KP-100, we report here our evaluation of the safety, tolerability, and pharmacokinetics of the investigational product KP-100 administered intrathecally to patients with ALS in Japan. Patients were given written informed consent forms approved by the institutional Ethics Committee and were fully informed about the study in writing, and then freely signed their consent forms. To reduce the burden on the subjects, the number of specimen collections, especially those requiring lumbar puncture, was minimized.
Methods

Ethics
Study Design
Subjects were enrolled in this open label study at the Tohoku University Hospital starting in January 2012 and followed up for about 50 days if given a single dose or for about 80 days if given multiple doses. Administration was initiated after 1 week of observation following the device implantation, and the device was withdrawn after 1 month of observation following the final administration. Additional 1-week observation was set after device withdrawal. The final observation took place in August 2014, the study period being 2 years 8 months. This clinical study was registered at the University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR, ID: UMIN000007062).
Subjects
Patients meeting all the following criteria were selected for inclusion as subjects in the study: (1) "clinically probable laboratory-supported ALS," "clinically probable ALS," or "clinically definite ALS," and within 3 years after onset according to the revised El Escorial criteria of the World Federation of Neurology; (2) ALS severity grade 1 or 2 as defined by the Survey and Research Group of Specific Diseases in the Ministry of Health, Labour and Welfare, January 1, 2007; (3) age ࣙ 20 years and < 65 years; (4) hospitalization possibly between the day before catheter implantation and the day of examination at least 15 days after singledose KP-100 administration or 43 days after multipledose administration; and (5) written informed consent to take part in the study obtained from the patient. To minimize the amount of residual KP-100 within the implanted device, physiological saline (a total of 2 mL) was also injected before and after the drug administration. Adverse events were monitored until day 36 of treatment, and the pharmacokinetics of KP-100 were evaluated. On day 36 of administration, the device was removed, and monitoring was continued for an additional 7 to 10 days. After 0.2-mg administration was completed (in 3 subjects), the dose was increased to 0.6 mg, then to 2.0 mg according to the high-dose shift criteria for single-dose administration.
As a rule, KP-100 was administered intrathecally (3 subjects) 5 times at 1-week intervals on the basis of preclinical pharmacokinetic data employing intrathecally administered Macaca fascicularis (data not shown) at the maximum dose (or at the dose determined based on review by the Efficacy and Safety Assessment Committee [ESAC]) with confirmed safety and tolerability in all 3 subjects receiving single-dose administration. However, depending on the pharmacokinetic data for single-dose administration, and based on review by the ESAC, we allowed multiple-dose administration at a dose lower than the maximum confirmed safe single dose, or allowed administration of 2 doses not more than the maximum dose confirmed to be safe in single-dose administration (n = 3 per dose). When multiple-dose administration groups received 2 doses, administration would be started at the lower dose and shifted to the higher dose according to the "Criteria for Shifting to Higher-dose Groups in Multiple-Dose Administration" after review by the ESAC. Regardless of the dose, intrathecal administration was repeated 5 times at 1-week intervals, as our preclinical, toxicologic data were limited to those of 4 weeks. Participants in the single-dose administration study were allowed to take part in the multiple-dose administration study. After the fifth dose was given in the same manner as single-dose administration, that is, through the same implanted spinal catheter with subcutaneous port, adverse events were followed up and the KP-100 pharmacokinetic profile was evaluated until day 36 after the last dose (day 64 after the first dose). At this time, the spinal catheter with subcutaneous port was removed and monitoring was continued for 7 to 10 days.
Assessment
Safety. Adverse events were identified using general assessment, vital signs, resting 12-lead electrocardiogram (ECG), blood biochemistry, hematology, bleeding coagulation test, urinalysis, and CSF test. Adverse events were classified by severity using Common Terminology Criteria for Adverse Events Version 4.0. With regard to device malfunctions, plain radiographic examination was performed to locate the catheter insertion before and after administration of KP-100. Subjective symptoms were monitored and evaluated during the implantation period. At the time of removal, the device was checked for damage to the catheter body and ports by visual inspection. The number of subjects experiencing adverse events and malfunctions, the number of onsets, and the incidence rates were calculated by dose and for the entire study population.
Changes over time in laboratory values before and after the start of administration of KP-100 were calculated by subject, and summary statistics were calculated by dose and for the entire study population at the various time points.
For the measurement of the anti-KP-100 antibody, a sample was added in a plate coated with KP-100, and antibodies were detected using biotinylated KP-100 and horseradish peroxidase avidin. With single-dose administration, anti-KP-100 antibody in the CSF was measured on the catheter implantation day, on days 15 and 29, and at the time of discontinuation, and anti-KP-100 antibody in the plasma was measured on the day before the catheter implantation, on days 15 and 29, and at the time of discontinuation. With multiple-dose administration, anti-KP-100 antibody in the CSF was measured on the catheter implantation day, on days 15 and 29 (before administration of KP-100), and on days 43 and 57, and anti-KP-100 antibody in the plasma was measured on the day before the catheter implantation day as well as on days 43 and 57.
Pharmacokinetics KP-100 concentrations in the CSF and the plasma were measured using an enzyme-linked immunosorbent assay kit (Immunis HGF EIA, Institute of Immunology Co., Ltd., Tokyo, Japan). With single-dose administration, the CSF KP-100 concentrations were measured 2 hours after completion of intrathecal administration and thereafter every 2 weeks, and the process of KP-100 elimination from the CSF was evaluated. KP-100 concentrations in the plasma were measured on the day before catheter implantation and on day 7, as well as on the day before the KP-100 administration; 1 and 4 hours after the KP-100 administration; on days 2, 3, 8, 15, and 29; and at the time of discontinuation. With multiple-dose administration, KP-100 concentrations were measured in the CSF at 2 hours after the first dose, and just before the third and fifth doses, to determine the presence/absence of KP-100 accumulation in the CSF during multiple-dose administration. KP-100 elimination from the CSF following multiple-dose administration was evaluated based on changes in KP-100 concentrations in the CSF measured after the fifth dose and 2 and 4 weeks later. KP-100 concentrations in the plasma were measured on the day before catheter implantation and on day 7, as well as on the day before the KP-100 administration, at 1 hour and 4 hours, and on day 7 after the KP-100 administration, at 4 hours and on days 1 and 7 after the second KP-100 administration, and at 4 hours and days 1, 14, and 28 after the last administration of KP-100. Pharmacokinetic parameters and all statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina). In addition, ALS progression was evaluated by functional assessment on the ALS functional rating scale (ALSFRS-R), 25 %FVC measurement, and neurological testing. On the ALSFRS-R, 12 daily activity parameters for ALS patients were each graded on a scale of 0 to 4 points, and the total of these 12 scores was used as an index of functional level.
Primary and Secondary End Points
The primary end points were the safety and tolerability of KP-100 as intrathecally administered. The secondary end points were the pharmacokinetic profile of KP-100 and the presence/absence of anti-KP-100 antibody production.
Target Sample Size
The target sample size was 3 subjects/group × 3 groups (9 subjects in total) for the single-dose regimen, and 3 subjects/group × 1 or 2 groups (3 or 6 subjects in total) for the multiple-dose regimen. Thus, the total sample size was 12 or 15 subjects.
Results
A total of 15 ALS subjects were assigned: 9 subjects (3 subjects/group × 3 groups) for single-dose administration, and 6 subjects (3 subjects/group × 2 groups) for multiple-dose administration (Figure 1 ). The mean age was 50.3 to 58.3 years, the mean duration of disease was 1.0 to 1.7 years, and the mean ALS functional score on ALSFRS-R per group was distributed between 41.0 and 45.0 points (Table 1 ). 
Pharmaceutical Characteristics
To establish a baseline for both single-dose and multiple-dose administrations, KP-100 was assessed in the CSF collected prior to the administration of KP-100 (on the catheter implantation day) in 6 of the 15 subjects (including 3 of the 9 subjects in the singledose group and 3 of the 6 subjects in the multipledose group); however, all the levels were lower than 1 ng/mL, with HGF levels detected at physiological concentrations or below. In the remaining 9 subjects, all the CSF KP-100 concentrations prior to the administration of KP-100 (on the catheter implantation day) were undetectable. Mean CSF KP-100 concentrations at 2 hours (± 1 hour) after single-dose administration were 729.9 ± 751.9 ng/mL for Group 1 (0.2 mg), 1804.3 ± 1328.6 ng/mL for Group 2 (0.6 mg), and 11566.8 ± 12408.6 ng/mL for Group 3 (2.0 mg); dose-dependent increases were followed by gradual elimination. In all 3 groups, even on day 15 of treatment, the KP-100 level remained higher than physiologic concentrations of HGF (Group 1, 0.5-0.7 ng/mL; Group 2, 1.0-1.5 ng/mL; Group 3, 1.9-5.2 ng/mL), with dose dependency demonstrated by the concentrations remaining in the CSF (Figure 2 ). On day 29 or at the time of discontinuation, the level was <1 ng/mL or the lower limit of detection in all 15 subjects. In the single-dose administration groups, the mean half-life of KP-100 in the CSF was 1.2 to 1.4 days ( Table 2) .
Mean KP-100 concentrations in the CSF obtained 2 hours (±1 hour) after the first dose of multipledose administration were 3004.1 ± 686.4 ng/mL in Group 4 (0.6 mg), and 11116.4 ± 5257.7 ng/mL in Group 5 (2.0 mg), with dose dependency demonstrated ( Table 3 ). The trough concentrations on day 15 of treatment (just before the third dose) and day 29 (just before the fifth dose) were nearly constant for all doses and dose dependent (>20 ng/mL in Group 4; >60 ng/mL in Group 5) (Figure 2) . Judging from the consistency of trough concentrations over time, there was no accumulation of the drug with multiple-dose administration for either the 0.6-mg or 2.0-mg dose. On day 43 (corresponding to 2 weeks after the end of the fifth dose), the trough concentration decreased to ࣘ10 ng/mL in both Groups 4 and 5; however, the analyte remained at concentrations higher than physiologic concentrations of HGF in both groups. On day 57, corresponding to 4 weeks after the fifth dose, the analyte concentration was <1 ng/mL in all 6 subjects.
In all the subjects, plasma KP-100 concentration was <1 ng/mL or below the lower limit of detection, and HGF concentration was not above its physiologic concentration at any time point of measurement prior to (catheter implantation period) and during the KP-100 treatment period. This finding suggested that little or no KP-100 was transported from the CSF to the plasma with either dose regimen. Anti-KP-100 antibody was not found in the CSF or the plasma in any of the subjects throughout the study period.
Safety
In this study, there were no deaths, serious adverse events/device malfunctions, or adverse events/device malfunctions leading to treatment discontinuation. A total of 69 adverse events were noted in 13 of the 15 subjects (Table 4 ). The number of adverse events by Medical Dictionary for Regulatory Activities preferred term was "post lumbar puncture syndrome" and "wound complication" in 10 subjects each, followed by "CSF protein increased" and "feeling abnormal," which means any kind of discomfort, in 9 subjects each, "constipation" in 4 subjects, and "contusion" and "back pain" in 2 subjects each; all other adverse events occurred in 1 subject only. The incidence of adverse events was not increased by multiple-dose administration relative to single-dose administration. As for severity, there were no Grade 3 or higher events and only 6 Grade 2 events with single-dose administration.
Forty adverse drug reactions (adverse events possibly caused by the investigational product) were observed in 12 of the 15 subjects. Such reactions by preferred term were "feeling abnormal" and "CSF protein increased" occurring in 9 subjects each, and "wound complication" in 5 subjects.
A total of 57 adverse events attributable to the investigational device were noted in 10 of the 15 subjects. By preferred term, these events were "post lumbar puncture syndrome" in 10 subjects, followed by "CSF protein increased" in 9 subjects, "feeling The last observation carried forward was used for imputation of the missing data for 1 subject in Group 2, who prematurely withdrew from the study. abnormal" in 8 subjects, and "wound complication" in 7 subjects. A device malfunction was noted in 1 multiple-dose subject in Group 5 (liquid feed failure) and was rated as "mild." Relationship of the event to the investigational product was ruled out, because the event occurred with administration of physiologic saline prior to administration of the investigational product.
During the catheter implantation period (before administration of KP-100) and the KP-100 treatment period, 8 of the 9 subjects receiving single-dose administration and 5 of the 6 subjects receiving multiple-dose administration had an abnormal general condition, most frequently headache and abnormal sensation in the lumbosacral region. These findings were reported as adverse events.
No marked changes or abnormalities in mean vital sign measurement or 12-lead ECG were noted throughout the study period. Mean CSF pressure tended to increase after single-dose administration and after the first dose of the multiple-dose regimen (310 mm CSF).
Similarly, no marked changes in mean values of hematology, blood biochemistry, blood coagulation, or urinalysis were found throughout the study period.
Mean cell count and protein concentration in the CSF were increased slightly at some time points during the KP-100 administration period (including discontinuations) compared with the catheter implantation period (prior to KP-100 administration) in all groups except Group 4, which showed no cell count increase. "CSF protein increased" occurred in 9 of the 15 subjects (5 of the 9 subjects receiving single-dose administration and 4 of the 6 subjects receiving multiple-dose administration) and "CSF cell count increased" occurred in 1 subject of Group 3. These adverse events were assessed as Grade 1, because of the small extent of the increase (protein concentration; <133 mg/dL, cell count; 11 cells/μL, only mononuclear cells) and the complete absence of related clinical symptoms and meningeal irritation signs. None of these events required treatment or procedural intervention, and all resolved spontaneously.
In response to a proposal by the ESAC, we statistically analyzed the data on the pleocytosis and the increased protein levels in the CSF for dose dependency and found no statistically significant differences in the increases among the various doses with either regimen and no statistically significant difference between single-dose administration and multiple-dose administration. In addition, functional assessment with ALSFRS-R (total score), %FVC measurement, and neurologic testing revealed almost no progression of ALS in any subjects during their participation in the study. This finding suggested that administration of the investigational product had no negative influence on the motor function.
Discussion
This is the first phase I study demonstrating the safety and tolerability of intrathecal KP-100 containing recombinant human dHGF as the active ingredient.
Because it is a large glycoprotein preparation (MW, 85 kDa) that cannot penetrate the blood-brain/spinal cord barrier, KP-100 delivery to the CNS is highly difficult by intravenous injection, and intrathecal administration ensures efficient delivery to the diseased site, like other pharmaceutical agents. 26, 27 To secure the intrathecal route of administration, surgery is required to insert a catheter into the lumbar spinal cavity, and to subcutaneously implant a dedicated port. Thus, the conduct of this study in healthy subjects was considered to pose ethical problems in view of the physical burden on the subject. Meanwhile, because of the possible effectiveness of the 5-dose regimen planned for this study on ALS, it was considered appropriate, despite being a phase I trial, to conduct this clinical trial in ALS patients. To assess the safety of KP-100 accurately, it is also appropriate not to enroll patients with rapidly progressing or advanced ALS, but to register those with slowly progressing early-stage ALS. Therefore, ALS patients with disease duration up to 3 years after onset and with an ALS severity grade (defined by Investigational Survey of Specified Diseases in the Ministry of Health, Labour and Welfare, January 1, 2007) of 1 or 2, indicative of independence in their daily life, were selected for inclusion in the study.
KP-100 itself, when intrathecally administered to ALS patients as a single dose (0.2 mg, 0.6 mg, 2.0 mg) or repeatedly (0.6 mg, 2.0 mg), has shown good safety and tolerability. A determination of the pharmacokinetic characteristics of KP-100 (active ingredient, dHGF) has shown that with single-dose administration, the mean half-life of KP-100 in the CSF was 1.2 to 1.4 days, with its maximum concentration increasing in a dosedependent manner. The pharmacokinetic data of the intravenous administration of dHGF in humans were already obtained in a previous clinical study, in which the clearance of blood dHGF showed 2 phases, with half-life of 17 ± 3 minutes in the α phase and 18.8 ± 5 hours in the β phase 28 comparison of these results reveals that KP-100 has demonstrated relatively longer half-life in the CSF than in the blood, and thus the treatment plan with intermittent administration of KP-100 is considered feasible. With multiple-dose administration, the trough KP-100 concentrations in the CSF are generally at constant levels for the various doses; therefore, it is concluded that KP-100 does not accumulate in the CSF with the multiple-dose administration.
Unlike this study, systemic/intravenous administration of dHGF was previously reported to have led to several adverse events, including mild to moderate flushing, dizziness, head throbbing, and so on (during or just after dosing), all of which disappeared within several minutes. 28 In contrast, such adverse events were not found in the present study employing intrathecal delivery of KP-100, even with multiple-dose administration. Additionally, there was no detectable transition from the CSF to the bloodstream (lower than physiologic concentration or below the lower limit of detection), suggesting substantial safety of the multiple-dose regimen in subsequent clinical trials.
At present, there are no other serious concerns associated with intrathecal KP-100 infusion. The mean CSF pressure tends to increase after single-dose administration or the first dose of the multiple-dose regimen. However, this increase may be a compensatory response due to the CSF leakage by catheter implantation, rather than an adverse event. In addition, increased protein levels and mononuclear pleocytosis in the CSF have been found in 1 subject (1 of 15; 6.7% of all subjects) in this study. Previous clinical trials also reported increases in the CSF protein levels and CSF lymphocytes without any meningitic symptoms after intrathecal administration of ciliary neurotrophic factor. 17 Similarly, we did not find any meningeal irritation signs or symptoms in the study. Moreover, the degrees of the CSF protein elevation and pleocytosis were mild and returned to preadministration levels with time. Hence, we have concluded that these issues were not critical for safety, even though the CSF monitoring is recommended for long-term administration.
Based on the present data, intrathecal infusion of KP-100 is expected to provide efficient delivery to the targeted CNS parenchyma, while avoiding both systemic adverse effects and possible KP-100-neutralizing antibody production. To extend the administration interval, an implantable and programmable pump may be feasible, although it is unavailable in our setting. Given that the data so far obtained have shown the efficacy of HGF in several CNS disease models, [29] [30] [31] [32] [33] therapeutic effects of intrathecal administration of KP-100 are expected in a variety of CNS diseases in the future, including ALS. ALS is a clinically and genetically heterogeneous syndrome, in which underlying pathomechanisms have been considered diverse. 34 Regardless of the pathogenesis, however, the pleiotropic effects of HGF on motor neurons and glial cells are promising for neuroprotection to suppress the disease progression of ALS. 22, 23, 28, 29 Currently, a double-blind placebo-controlled phase II trial in patients with ALS and a double-blind placebo-controlled phase I/II study in those with acute spinal cord injury are ongoing to evaluate therapeutic efficacy of KP-100. Detailed discussion on the efficacy of HGF will be done in the next report of the phase II trial.
Conclusions
The investigational product KP-100 administered intrathecally to subjects with early-stage ALS as a single dose (0.2 mg, 0.6 mg, 2.0 mg) or repeatedly (0.6 mg, 2.0 mg) has been suggested to be safe and tolerable. There seems to be almost no accumulation of the drug in the CSF, no transport of the drug from the CSF into the bloodstream, and no evidence of anti-KP-100 antibody production; therefore, the further testing of KP-100 in a phase II exploratory trial for patients with ALS is considered safe. Based on the safety of the intrathecal administration of KP-100 confirmed in the present study, novel therapeutic approaches to various CNS diseases using KP-100 are anticipated.
